Navigation Links
Sangamo BioSciences Presents Clinical Data From Key SB-728-T HIV Studies: Proof Of Concept For Ongoing Sustained Functional Control Of HIV Viral Load; Cytoxan Preconditioning Successfully Enhances Engraftment
Date:12/6/2013

RNA levels are >10,000 copies/ mL for three consecutive weeks or their CD4 T-cell count drops below 500 cells/mm3 for two consecutive weekly measurements.

Two additional cohorts of three subjects each will be treated at doses of 2000mg/m2 and 3000mg/m2, respectively.

About SB-728-T
Sangamo's drug, SB-728-T, is generated by ZFN-mediated modification of the gene encoding the CCR5 receptor in a patient's own T-cells.  ZFN modification disrupts the expression of this key co-receptor for HIV entry and renders cells resistant to HIV infection. The approach is based on the observation that a naturally occurring mutation in the CCR5 gene, CCR5 delta-32, provides protection from HIV infection. Individuals in whom both copies of the CCR5 gene carry the delta-32 mutation are generally not susceptible to the most common strain of HIV.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 and Phase1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. As part of its acquisition of Ceregene Inc., Sangamo acquired a fully-enrolled and funded, double-blind, placebo-controlled Phase 2 trial to evaluate NGF-AAV (CERE-110) in Alzheimer's disease. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell fun
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
2. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
3. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
4. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
5. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
6. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
7. Sangamo BioSciences Reports First Quarter 2013 Financial Results
8. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
9. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
10. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
11. Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)...   NuAire , a manufacturer of ergonomically designed laboratory equipment ... of Japan to sell and service ... . NuAire will utilize its network of sales professionals throughout ... to offer assistance in application use, product benefits and features, ...
(Date:1/14/2014)... Oligomerix, Inc. , a privately held company pioneering the ... and related neurodegenerative disorders, announced today the relocation of ... as of January 15, 2014 and expanded lease ... College. Oligomerix, which is focused on the ...
(Date:1/14/2014)... Evidera , a leading provider of evidence-based solutions for ... Evaluation and Research (CDER), U.S. Food and Drug Administration, ... a patient-reported outcome (PRO) measure in drug development: ... for Measurement of Symptoms of Acute Bacterial Exacerbation of ...
Breaking Medicine Technology:NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
... Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ), announced ... drug designation for tasimelteon, an oral dual melatonin receptor ... Disorder (N24HSWD) in blind individuals with no light perception. ... the Committee for Orphan Medicinal Products (COMP) of the ...
... BrainScope Company, Inc. announced today that it is ... product in development to aid in the assessment of ... the potential to represent a significant advancement in the ... injury (TBI) (including its milder forms commonly referred to ...
Cached Medicine Technology:Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 2Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 3Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 4BrainScope® Prepares to Introduce Ahead™ EU-100 to Aid in Assessment of Head Injury in the United Kingdom 2BrainScope® Prepares to Introduce Ahead™ EU-100 to Aid in Assessment of Head Injury in the United Kingdom 3
(Date:7/9/2014)... of flatulence and have a reputation for being highly toxic, ... is now being being found to offer potential health benefits ... attacks and dementia. A new compound (AP39), designed and made ... future therapies, by targeting delivery of very small amounts of ... , Scientists in Exeter have already found that the ...
(Date:7/9/2014)... A retrospective study conducted by researchers at Tufts University ... adults with intellectual and developmental disabilities, the likelihood of ... dental care increased. The findings, published in the July/August ... help improve interventions designed to address the oral health ... reviewed the dental records of 107 patients at one ...
(Date:7/9/2014)... , , , , ... , , , AUDIO: , ... approximately 30cm from the bullet... , , Click here for ... , , , , , ... , , , , , University of Southampton researchers, with assistance from the Ministry of ...
(Date:7/9/2014)... School of Medicine of the University of Southern ... specific component of the immune system are completely ... infection. The discovery suggests that blocking this immune ... autoimmune and hyper-inflammatory diseases such as rheumatoid arthritis ... published online on June 23 in The ...
(Date:7/8/2014)... The Department of Defense,s Defense Advanced Research Projects ... up to $2.5 million to develop an implantable ... stimulate neurons within the brain to help restore ... research builds on the understanding that memory is ... of the brain encode information, store it and ...
Breaking Medicine News(10 mins):Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3
... ... ... Tony Rico has recently been promoted to Senior Vice President of Operations at Jackson ... 1, 2009. , , , , ,"This position has been vacant for a ...
... On Tuesday, October 20, 2009, at 1:00 PM Eastern Time/10:00 AM ... (Nasdaq and MTA: CTIC) management team will host an Annual Meeting of ... WA 98119. The meeting will also be webcast live on CTI,s website ... ...
... being stifled by a U.S. law and successful patent challenges ... this week,s issue of the journal Science . ... of Management at the Georgia Institute of Technology, argue in ... challenges -- a provision of the Hatch-Waxman Act of 1984 ...
... After the Austin City Limits music festival concluded, spa ... Austin, Tx. for the 19th annual International SPA Association ... spa community, participated in educational sessions, learned about the ... The Conference theme, "Simplify," resonated with attendees as ...
... National Awareness Campaign to Combat Breast Cancer has been ... Awareness month. The campaign is led by Princess Hessah bint Trad ... wife of the Custodian of the Two Holy Mosques ... bin Abdulaziz. It officially launched on October 10. , As ...
... scientists interested in finance, entrepreneurships and the chemical sciences are ... Medium Business Webinar for an opportunity to learn about trends ... Scheduled for Thursday, Oct. 22, 2 3 p.m. ... of International eChem and author of the well-regarded ICIS "Chemicals ...
Cached Medicine News:Health News:Jackson & Coker Promotes Tony Rico to Senior VP of Operations 2Health News:Cell Therapeutics, Inc. Annual Meeting of Shareholders Scheduled for Tuesday, October 20, 2009 2Health News:Patent challenges reduce pharmaceutical innovation and productivity, researchers suggest 2Health News:Patent challenges reduce pharmaceutical innovation and productivity, researchers suggest 3Health News:2009 ISPA Conference & Expo Rocks Out With Lance Armstrong in Austin 2
... An APTT-based assay for the detection ... poor anticoagulant response to activated protein C ... an estimation of the anticoagulant function in ... risk associated with inherited and acquired APC ...
Inquire...
Each Uro-Safe® vinyl leg bag is hand-tested for defects through each phase of the manufacturing process and packaged individually in a sterile, easy, peel-open pouch with two latex leg straps....
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
Medicine Products: